Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of W. Michael Korn, M.D., as its chief medical...

Related Keywords

Germany ,West German ,W Michael Korn ,Amanda Mcquery ,Robert Nussbaum ,Linkedin Invitae ,Precision Oncology Initiative ,York Stock Exchange Rule ,Philipps University Marburg ,University Hospital Essen ,Exchange Commission ,Invitae Corporation ,Division Of Hematology Oncology ,Caris Life Sciences ,University Of California San Francisco ,German Cancer Center ,Caris Life ,California San Francisco ,Molecular Tumor Board ,West German Cancer Center ,University Hospital ,Incentive Plan ,New York Stock Exchange Rule ,Harbor Statement ,Private Securities Litigation Reform Act ,Annual Report ,